Page
%P
2 Result(s)
within
Yosuke Hirasawa
Cancer Research
-
Article
Open AccessComparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Enfortumab vedotin (EV) is a novel antibody–drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in e...
-
Article
Open AccessClinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone
This study investigated the association between apparent diffusion coefficients in Prostate Imaging Reporting and Data System 4/5 lesions and clinically significant prostate cancer in the transition zone.
